News Headlines

  1. eXmoor Pharma And Siam Bioscience Form Strategic Partnership To Establish Leading CGT Services In Southeast Asia 9/23/2025

    eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company in ASEAN, today announced a strategic partnership to build the region’s foremost centre for Cell and Gene Therapy (CGT) development and manufacturing.

  2. Lilly Plans To Build A New $6.5B Facility To Manufacture Active Pharmaceutical Ingredients In Texas 9/23/2025

    Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. This planned next-generation synthetic medicine active pharmaceutical product (API) facility, the second of four new U.S. sites Lilly will announce this year, will focus on manufacturing the company's pipeline of small molecule medicines across therapeutic areas, including cardiometabolic health, oncology, immunology and neuroscience. It is expected to be operational within five years.

  3. RION Engages Lonza To Scale Manufacturing Exosome Based Therapeutics 9/23/2025

    RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal health applications, has announced a collaboration with Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product (PEP) drug substance for late phase clinical supply and beyond. 

  4. Pfizer To Acquire Metsera And Its Next-Generation Obesity Portfolio 9/22/2025

    Pfizer Inc. and Metsera, Inc. today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.

  5. Mikart And Nano Pharmasolutions Announce Positive Interim Data From NT-301 Phase 1 Trial And Expansion Of NanoTransformer® Manufacturing Capabilities 9/18/2025

    Mikart, LLC, a leading contract development and manufacturing organization (CDMO), and Nano PharmaSolutions, Inc. (NPS), a nanodrug delivery pharmaceutical company, today announced positive safety and pharmacokinetics data from the ongoing Phase 1 clinical trial of NT-301, a proprietary powder nasal spray being developed for the treatment of Parkinson's disease OFF episodes.

  6. FUJIFILM Biotechnologies Expands Strategic Partnership With Argenx To Include U.S. Manufacturing Operations 9/18/2025

    FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company.

  7. Kindeva Opens New UK HQ And Manufacturing Site For The Development Of Next-Generation Propellants 9/18/2025

    Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough.

  8. Sartorius Stedim Biotech Expands Production Of Key Components For Cell And Gene Therapies In France 9/18/2025

    Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has expanded its site in Illkirch near Strasbourg in France.

  9. GSK To Invest $30B In R&D And Manufacturing In The United States Over Next 5 Years 9/17/2025

    GSK plc today announced plans to invest $30B across the United States in research and development and supply chain infrastructure over the next five years.

  10. Wheeler Bio And MindImmune Therapeutics Sign CDMO Partnership Agreement To Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101 9/17/2025

    Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), today announced it has entered into an agreement with MindImmune Therapeutics, a biopharmaceutical company focused on neuroinflammation and Alzheimer's disease.